Literature DB >> 11248824

Bacteriologic and clinical efficacy of ofloxacin 0.3% versus ciprofloxacin 0.3% ophthalmic solutions in the treatment of patients with culture-positive bacterial keratitis.

N V Prajna1, C George, S Selvaraj, K L Lu, P J McDonnell, M Srinivasan.   

Abstract

PURPOSE: To compare the efficacy and safety of ofloxacin 0.3% ophthalmic solution with ciprofloxacin 0.3% ophthalmic solution in patients with culture-positive bacterial keratitis.
METHODS: Patients with a microbiologic diagnosis of bacterial keratitis were included in this double-masked, parallel-group study and were randomized to treatment with either ofloxacin 0.3% or ciprofloxacin 0.3% ophthalmic solution. One drop of the study medication was instilled during the daytime according to the following schedule: every half-hour on study day 1, every hour on days 2 through 4, and every 2 hours on days 5 through 21. Healing, the primary outcome measure, was defined as complete reepithelialization, accompanied by nonprogression of stromal infiltrate for 2 days. Secondary outcome measures included signs and symptoms of infection. Patients were monitored throughout the study period for any adverse events.
RESULTS: A total of 217 patients completed the study: 112 were treated with ofloxacin and 105 were treated with ciprofloxacin. Streptococcus pneumoniae was the most commonly encountered pathogen in all patients. Complete corneal reepithelialization occurred in 85% of those treated with ofloxacin and in 77% of those treated with ciprofloxacin (p = 0.32). The average time to corneal ulcer healing was 13.7 days in those treated with ofloxacin and 14.4 days in those treated with ciprofloxacin. Both treatments were well tolerated with no patient discontinuing the study because of side effects.
CONCLUSION: Ofloxacin 0.3% and ciprofloxacin 0.3% ophthalmic solutions are effective and safe in the treatment of patients with culture-positive bacterial keratitis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11248824     DOI: 10.1097/00003226-200103000-00013

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  7 in total

1.  Corneal deposits after the topical use of ofloxacin in two children with vernal keratoconjunctivitis.

Authors:  I Claerhout; Ph Kestelyn; F Meire; J-P Remon; T Decaestecker; J Van Bocxlaer
Journal:  Br J Ophthalmol       Date:  2003-05       Impact factor: 4.638

Review 2.  Update on the Management of Infectious Keratitis.

Authors:  Ariana Austin; Tom Lietman; Jennifer Rose-Nussbaumer
Journal:  Ophthalmology       Date:  2017-09-21       Impact factor: 12.079

3.  Penetration of topically applied levofloxacin 0.5% and ofloxacin 0.3% into the vitreous of the non-inflamed human eye.

Authors:  Tuomo Puustjärvi; Markku Teräsvirta; Pila Nurmenniemi; Jukka Lokkila; Hannu Uusitalo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-12       Impact factor: 3.117

4.  A mucoadhesive polymer extracted from tamarind seed improves the intraocular penetration and efficacy of rufloxacin in topical treatment of experimental bacterial keratitis.

Authors:  Emilia Ghelardi; Arianna Tavanti; Paola Davini; Francesco Celandroni; Sara Salvetti; Eva Parisio; Enrico Boldrini; Sonia Senesi; Mario Campa
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

5.  Corticosteroids for bacterial corneal ulcers.

Authors:  M Srinivasan; P Lalitha; R Mahalakshmi; N V Prajna; J Mascarenhas; J D Chidambaram; S Lee; K C Hong; M Zegans; D V Glidden; S McLeod; J P Whitcher; T M Lietman; N R Acharya
Journal:  Br J Ophthalmol       Date:  2008-10-01       Impact factor: 4.638

6.  A randomised clinical trial comparing 2% econazole and 5% natamycin for the treatment of fungal keratitis.

Authors:  N V Prajna; R K John; P K Nirmalan; P Lalitha; M Srinivasan
Journal:  Br J Ophthalmol       Date:  2003-10       Impact factor: 4.638

7.  The efficacy and safety of topical polymyxin B, neomycin and gramicidin for treatment of presumed bacterial corneal ulceration.

Authors:  M I Bosscha; J T van Dissel; E J Kuijper; W Swart; M J Jager
Journal:  Br J Ophthalmol       Date:  2004-01       Impact factor: 4.638

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.